Jan H Terheyden1, Robert P Finger2, Steffen Schmitz-Valckenberg1, Hansjürgen Agostini3, Claudia Dahlke4, Laura Kuehlewein5, Gabriele E Lang6, Daniel Pauleikhoff7, Armin Wolf8, Michael K Boettger9, Ulrich F O Luhmann10, Friedrich Asmus11, Frank G Holz12. 1. Universitäts-Augenklinik Bonn, Bonn, Deutschland. 2. Universitäts-Augenklinik Bonn, Bonn, Deutschland. robert.finger@ukbonn.de. 3. Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Freiburg, Deutschland. 4. Zentrum für Augenheilkunde, Uniklinik Köln, Köln, Deutschland. 5. Universitäts-Augenklinik und Forschungsinstitut für Augenheilkunde, Tübingen, Deutschland. 6. Universitäts-Augenklinik Ulm, Ulm, Deutschland. 7. Augenzentrum, St. Franziskus-Hospital, Münster, Deutschland. 8. Augenklinik, Ludwig-Maximilians-Universität, München, Deutschland. 9. Pharmaceuticals, Clinical Sciences Experimental Medicine, Bayer AG, Wuppertal, Deutschland. 10. Roche Pharmaceutical Research and Early Development, Translational Medicine Ophthalmology, Roche Innovation Center Basel, Basel, Schweiz. 11. Pharmaceuticals, Clinical Development Ophthalmology, Bayer AG, Berlin, Deutschland. 12. Universitäts-Augenklinik Bonn, Bonn, Deutschland. frank.holz@ukbonn.de.
Abstract
BACKGROUND: Currently, no validated clinical endpoints for treatment studies exist for intermediate age-related macular degeneration (iAMD). OBJECTIVE: The European MACUSTAR study aims to develop and clinically validate adequate clinical endpoints for future treatment studies in iAMD and to identify early determinants of disease progression to late stage AMD. MATERIAL AND METHODS: The MACUSTAR study protocol was developed by an international consortium of researchers from academia, the pharmaceutical industry and medical device companies. The MACUSTAR project is funded by the Innovative Medicines Initiative 2 (IMI2) of the European Union. RESULTS: The MACUSTAR study consists of a cross-sectional and a longitudinal investigation. A total of 750 subjects with early, intermediate and late AMD as well as control subjects with no signs of AMD will be included with a follow-up period of 3 years. Overall, 20 European study centers are involved. CONCLUSION: The MACUSTAR project will generate large high-quality datasets, which will allow clinical validation of novel endpoints for future interventional trials in iAMD. The aim is that these endpoints will be accepted as suitable for medication approval studies by the regulatory authorities and that understanding of the disease process will be improved.
BACKGROUND: Currently, no validated clinical endpoints for treatment studies exist for intermediate age-related macular degeneration (iAMD). OBJECTIVE: The European MACUSTAR study aims to develop and clinically validate adequate clinical endpoints for future treatment studies in iAMD and to identify early determinants of disease progression to late stage AMD. MATERIAL AND METHODS: The MACUSTAR study protocol was developed by an international consortium of researchers from academia, the pharmaceutical industry and medical device companies. The MACUSTAR project is funded by the Innovative Medicines Initiative 2 (IMI2) of the European Union. RESULTS: The MACUSTAR study consists of a cross-sectional and a longitudinal investigation. A total of 750 subjects with early, intermediate and late AMD as well as control subjects with no signs of AMD will be included with a follow-up period of 3 years. Overall, 20 European study centers are involved. CONCLUSION: The MACUSTAR project will generate large high-quality datasets, which will allow clinical validation of novel endpoints for future interventional trials in iAMD. The aim is that these endpoints will be accepted as suitable for medication approval studies by the regulatory authorities and that understanding of the disease process will be improved.
Authors: Maximilian Pfau; Moritz Lindner; Martin Gliem; Julia S Steinberg; Sarah Thiele; Robert P Finger; Monika Fleckenstein; Frank G Holz; Steffen Schmitz-Valckenberg Journal: Eye (Lond) Date: 2018-08-01 Impact factor: 3.775
Authors: Julia S Steinberg; Fred W Fitzke; Rolf Fimmers; Monika Fleckenstein; Frank G Holz; Steffen Schmitz-Valckenberg Journal: JAMA Ophthalmol Date: 2015-06 Impact factor: 7.389
Authors: Sarah Thiele; Jennifer Nadal; Monika Fleckenstein; Petra P Fang; Maximilian Pfau; Matthias Schmid; Rui Hua; Frank G Holz; Steffen Schmitz-Valckenberg Journal: Ophthalmologica Date: 2018-01-05 Impact factor: 3.250
Authors: Robert P Finger; Steffen Schmitz-Valckenberg; Matthias Schmid; Gary S Rubin; Hannah Dunbar; Adnan Tufail; David P Crabb; Alison Binns; Clara I Sánchez; Philippe Margaron; Guillaume Normand; Mary K Durbin; Ulrich F O Luhmann; Parisa Zamiri; José Cunha-Vaz; Friedrich Asmus; Frank G Holz Journal: Ophthalmologica Date: 2018-08-28 Impact factor: 3.250
Authors: Frederick L Ferris; C P Wilkinson; Alan Bird; Usha Chakravarthy; Emily Chew; Karl Csaky; SriniVas R Sadda Journal: Ophthalmology Date: 2013-01-16 Impact factor: 12.079
Authors: Monica B Sevilla; Gerald McGwin; Eleonora M Lad; Mark Clark; Eric L Yuan; Sina Farsiu; Christine A Curcio; Cynthia Owsley; Cynthia A Toth Journal: Am J Ophthalmol Date: 2016-03-03 Impact factor: 5.258
Authors: Cynthia Owsley; Gerald McGwin; Mark E Clark; Gregory R Jackson; Michael A Callahan; Lanning B Kline; C Douglas Witherspoon; Christine A Curcio Journal: Ophthalmology Date: 2015-10-30 Impact factor: 12.079
Authors: Julia S Steinberg; Marlene Saßmannshausen; Maximilian Pfau; Monika Fleckenstein; Robert P Finger; Frank G Holz; Steffen Schmitz-Valckenberg Journal: Transl Vis Sci Technol Date: 2017-07-13 Impact factor: 3.283
Authors: Marlene Saßmannshausen; Charlotte Behning; Ben Isselmann; Matthias Schmid; Robert P Finger; Frank G Holz; Steffen Schmitz-Valckenberg; Maximilian Pfau; Sarah Thiele Journal: Sci Rep Date: 2022-09-02 Impact factor: 4.996
Authors: Divya Narayanan; John Rodriguez; Garrick Wallstrom; Donna Welch; Matthew Chapin; Paul Arrigg; Mark Abelson Journal: BMC Ophthalmol Date: 2020-10-22 Impact factor: 2.209